A Novel Approach to Antimicrobial Resistance: Machine Learning Predictions for Carbapenem-Resistant Klebsiella in ICUs
Study Details
Study Description
Brief Summary
The aim of this study to predict carbapenem resistant Klebsiella spp. earlier in our patients monitored in our Intensive Care Unit in the future, using artificial intelligence.
Patients with bloodstream infection and pneumonia caused by Klebsiella spp. will be comparatively examined in two groups, as sensitive and resistant. Resistance will be attempted to be predicted with deep machine learning.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Antimicrobial resistance is a globally increasing threat and has serious consequences on both public health and the economy. In an infection that may develop with a resistant microorganism, therapeutic options are limited, hence early and effective treatment that can be initiated by predicting resistance will make a difference in patient prognosis.
Today, artificial intelligence and machine learning are changing our medical practice. When the literature is reviewed, there are studies suggesting that machine learning can predict antimicrobial resistance.Risk factors for carbapenem-resistant Klebsiella spp. have been previously identified. These previously identified risk factors will be evaluated retrospectively in our own patients and an algorithm related to the prediction of resistance will be developed with the help of machine learning.
Our goal is to predict bacterial resistance earlier in our patients monitored in our Intensive Care Unit in the future, using artificial intelligence, and to facilitate our patients' access to early and effective treatment options.
Secondarily, it is also aimed to provide economic benefits by preventing unnecessary antibiotic use.
Access to patients' data will be obtained retrospectively through the hospital automation system.
Publications in the literature will be examined, and the risk factors causing the development of infection with carbapenem-resistant Klebsiella spp. will be evaluated.
Patients with carbapenem resistance and sensitivity will be compared in two separate subgroups.
The obtained features will be classified using various decision trees and neural algorithms separately. The data obtained will be statistically compared in the distinction of resistance and sensitivity. Statistical evaluation was done with IBM SPSS 29.0 (IBM Corp., Armonk, NY, USA). Demographic data, descriptive statistics, Categorical variables will be expressed in terms of frequency (percentage).
Categorical variables will be expressed with the chi-square test. The performance of Machine Learning algorithms will be evaluated by ROC analysis, AUC, classification accuracy, sensitivity, and specificity values will be calculated.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Patients with carbapenem resistant Klebsiella spp. infection
|
Other: Artificial intelligence
Prediction of carbapenem resistance via deep machine learning model
|
| Patients with carbapenem sensitive Klebsiella spp. infection
|
Other: Artificial intelligence
Prediction of carbapenem resistance via deep machine learning model
|
Outcome Measures
Primary Outcome Measures
- To predict bacterial resistance via artifical intelligence [3 months]
Our goal is to predict bacterial resistance earlier in our patients monitored in our Intensive Care Unit in the future, using artificial intelligence, and to facilitate our patients' access to early and effective treatment options.
Secondary Outcome Measures
- To provide economic benefit [3 months]
Secondarily, it is also aimed to provide economic benefits by preventing unnecessary antibiotic use.
Eligibility Criteria
Criteria
Inclusion Criteria:
Patients monitored in our third-level intensive care unit between June 2017 and June 2023 will be evaluated retrospectively. Patients with pneumonia and bloodstream infection developed with Klebsiella spp. will be included in the study.
Exclusion Criteria:
-
Patients under the age of 18 have not been included in the study.
-
Infections outside of the respiratory tract and bloodstream have not been included in the study.
-
Patients with respiratory tract colonization and without active inflammation have also not been included.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Kocaeli University | Kocaeli | Turkey |
Sponsors and Collaborators
- Kocaeli University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- GOKAEK-2023/12.32